Begzema 58%, Herzuma 76%

Expanding Portfolio with New Products

Celltrion announced on March 16 that its oncology biosimilar products continue to maintain a high prescription market share in Japan.

Celltrion Company Logo Image. Celltrion

Celltrion Company Logo Image. Celltrion

View original image

According to pharmaceutical market research firm IQVIA and local data, as of December last year, Celltrion's bevacizumab biosimilar "Begzema" held a 58% market share in Japan. This figure surpasses the combined market share of four competing products, including the original drug Avastin.


Begzema, an anticancer agent used in the treatment of metastatic colorectal cancer and breast cancer, is the top prescribed product in a Japanese market where five products compete. Its market share exceeded 50% in September last year and has continued to rise since then.


The trastuzumab biosimilar "Herzuma," which was launched earlier, also remains strong in the Japanese market. As of the same period, Herzuma's market share stood at 76%, accounting for approximately three-quarters of the trastuzumab prescription market in Japan.


Since its launch in Japan in 2019, prescriptions for Herzuma have rapidly increased. In the second quarter of 2021, it exceeded the market share of the original drug Herceptin for the first time and has maintained the top prescription position for about four and a half years.


Celltrion explained that Japan's Diagnosis Procedure Combination (DPC) system has created a favorable environment for the adoption of biosimilars. Under this system, medical institutions can retain a portion of the cost savings when they use lower-priced pharmaceuticals.


Celltrion is also expanding its market share in treatments for autoimmune diseases. The infliximab biosimilar "Remsima" held a 43% market share in Japan, while the adalimumab biosimilar "Yuflyma" achieved a 17% market share, recording the highest prescription volume among biosimilars.


Celltrion plans to further expand its product portfolio in Japan this year. After launching the ustekinumab biosimilar "Stekyma" in August last year, Celltrion is scheduled to introduce the tocilizumab biosimilar "Aptozma" in the second quarter of this year.



Ho-woong Kim, Vice President of Global Sales at Celltrion, stated, "Our major products continue to lead prescriptions in the Japanese market," and added, "We will strengthen our market competitiveness through the launch of new products."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing